VANTAS®
This product information is intended for U.S. residents only.
VANTAS® (histrelin implant) is a soft and flexible 12-month hydrogel implant that provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer. The product utilizes the Company’s patented HYDRON® Polymer Technology that allows for a controlled delivery of medicine over a 12-month period.
LHRH agonist therapy is the current standard of care for the palliative treatment of advanced prostate cancer by suppressing the production of testosterone. Testosterone is believed to promote the growth of tumors associated with prostate cancer. Histrelin, the active medicine in VANTAS, is a potent LHRH agonist and a powerful inhibitor of testosterone production. VANTAS is presently the only once- yearly histrelin therapy indicated for the palliative treatment of advanced prostate cancer.
Visit
www.vantasimplant.com to learn more
- VANTAS® is indicated in the palliative treatment of advanced prostate cancer.
- Important Safety Information
- VANTAS is contraindicated in women, pediatric patients and patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the other components of VANTAS.
- VANTAS, like other LHRH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience worsening of symptoms or onset of new symptoms, including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, cases of ureteral obstruction and spinal cord compression. Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.
- Implant insertion and removal is a surgical procedure and should use aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended. In all clinical trials combined, an implant was not recovered in 8 patients, 2 of these 8 patients had serum testosterone levels above castrate level and the implant was not visualized with ultrasound. In all of the 8 patients, the implant was not palpable.
- Response to VANTAS should be monitored measuring serum concentrations of testosterone and PSA periodically.
- In clinical trials, the most common adverse reactions were hot flashes, fatigue, and implant site reaction. During post-marketing surveillance, rare cases of pituitary apoplexy have been reported after the administration of GnRH agonists.
- Please see the accompanying Full Prescribing Information for VANTAS.
VANTAS® is a registered trademark of Endo Pharmaceuticals
*By clicking on the link(s) on this page you will leave the Endo.com website and move to an external website(s) independently operated and not managed by Endo Pharmaceuticals. Because Endo Pharmaceuticals does not control the content of the website(s) you are about to visit, and due to its constantly changing nature, we cannot be responsible for its content, accuracy, practices, or standards.
